Cempra, Inc. (CEMP) Downgraded to “Sell” at Zacks Investment Research

Zacks Investment Research downgraded shares of Cempra, Inc. (NASDAQ:CEMP) from a hold rating to a sell rating in a report published on Tuesday.

According to Zacks, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina. “

A number of other equities research analysts also recently commented on the company. Jefferies Group LLC reiterated a hold rating and issued a $3.00 price objective on shares of Cempra in a report on Thursday, September 14th. Roth Capital downgraded Cempra from a buy rating to a neutral rating and dropped their price objective for the company from $8.00 to $4.00 in a report on Thursday, August 10th. Finally, Stifel Nicolaus reiterated a hold rating and issued a $4.00 price objective on shares of Cempra in a report on Thursday, August 10th. Five equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $10.00.

Cempra (NASDAQ:CEMP) opened at 3.20 on Tuesday. Cempra has a 52 week low of $2.55 and a 52 week high of $24.48. The stock’s market cap is $168.02 million. The company has a 50-day moving average price of $3.09 and a 200-day moving average price of $3.73.

Cempra (NASDAQ:CEMP) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.09. The business had revenue of $0.86 million during the quarter, compared to the consensus estimate of $3.58 million. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The firm’s revenue was down 74.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.51) earnings per share. Analysts anticipate that Cempra will post ($1.01) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Cempra, Inc. (CEMP) Downgraded to “Sell” at Zacks Investment Research” was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.themarketsdaily.com/2017/10/11/cempra-inc-cemp-downgraded-to-sell-at-zacks-investment-research.html.

Large investors have recently bought and sold shares of the stock. Voya Investment Management LLC grew its holdings in shares of Cempra by 34.1% during the second quarter. Voya Investment Management LLC now owns 23,006 shares of the biotechnology company’s stock worth $106,000 after buying an additional 5,848 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Cempra by 35.6% during the second quarter. Janney Montgomery Scott LLC now owns 25,900 shares of the biotechnology company’s stock worth $119,000 after buying an additional 6,800 shares in the last quarter. Asset Management One Co. Ltd. bought a new position in shares of Cempra during the first quarter worth about $106,000. LMR Partners LLP bought a new position in shares of Cempra during the second quarter worth about $149,000. Finally, Ameriprise Financial Inc. bought a new position in shares of Cempra during the second quarter worth about $164,000. Institutional investors and hedge funds own 49.75% of the company’s stock.

Cempra Company Profile

Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

Analyst Recommendations for Cempra (NASDAQ:CEMP)

Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply